

Bringing probiotics to life

Product Portfolio

Biotic formulas built for life




We are a global probiotic manufacturer driven by science

At the forefront of an expanding field, we develop **cutting-edge biotic solutions** backed by robust scientific evidence. Our offering spans from proprietary strains to tailored formulations and market-ready products:



Probiotic strains

Unique strains with characterised mechanisms of action



Probiotic formulas

Scientifically documented, forward-looking probiotic solutions



Market-ready products


Premium probiotic products adapted to your market

How we deliver

In bulk, secondary or tertiary packaging—available as private label or under our brand.

Our development process

We use a pioneering **top-down approach**, starting with a broad range of strains and narrowing to those that meet our strict criteria.



KABP® – Quality you can trust

KABP® is the **designation** for each of our proprietary probiotic strains, ensuring traceability, quality, and consistency. It represents the link between our strains, their validated clinical evidence, and our strict manufacturing standards.



Fully compliant with FAO/WHO and ISAPP definitions of probiotics and postbiotics. **Clinically-proven** with at least one randomized, double-blind, placebo-controlled clinical trial.



European manufacturing, with stability guaranteed until end of shelf life.



Safety first: continuous monitoring and HACCP-based quality control at every stage. Strains with **QPS status** (EFSA), **GRAS status** (FDA) and/or **Natural Product Number** (Health Canada).



State-of-the-art facilities, developed in line with ISAPP recommendations and Codex Alimentarius food safety guidelines, and certified by GMP, FSSC 22000, Pharma Lab, and FDA.

Product Portfolio Overview

Probiotics

Postbiotics

	Food Supplements	Functional Foods	OTC Drugs <i>under development</i>	Food Supplements	Medical Devices	Cosmetics
Gastro-intestinal health	i3.1 AB-Digest IS-2	i3.1 IS-2	i3.1 <i>S. boulardii</i> <i>B. clausii</i>			
Pediatric health	AB-Kolicare AB-Sakei 65 AB21 AB-Digest Mindbiome Plus	AB-Kolicare		AB-Sakei 65		AB-Sakei 65
Oral health	AB-Dentalac Dentisani					Dentisani
Cognitive health	Mindbiome Mindbiome Plus					
Cardio-metabolic health	AB-LIFE Mindbiome				Lipigo	
Immune health	AB-DR7 AB21	AB-DR7				
Healthy ageing	Innerim LB-P12 AB-LIFE AB-Sakei 65 Gyntima Menopause			AB-Sakei 65		AB-Sakei 65 BL+PA
Eye health					AB-Protears	
Women's health	Gyntima Cyscare Gyntima Balance Gyntima Menopause Gyntima Fertility			Gyntima Restore Gyntima Iron	Gyntima Restore	
Skin health	AB-Sakei 65			AB-Sakei 65 Gyntima Iron		AB-Sakei 65 BL+PA
Sport health	i3.1 TWK10 IS-2			Gyntima Iron		

Dive into the scientific evidence here:



Therapeutic areas we address – Food supplements and medical devices

Gastrointestinal health

i3.1®

P. acidilactici KABP® 021
L. plantarum KABP® 022
L. plantarum KABP® 023

AB-DIGEST

B. longum KABP® 042
P. pentosaceus KABP® 041
L. rhamnosus GG

Pediatric health

AB-KOLICARE®

B. longum KABP® 042
P. pentosaceus KABP® 041

Oral health

AB-DENTALAC®

L. plantarum KABP® 051
L. brevis KABP® 052
P. acidilactici KABP® 053

DENTISANI

S. dentisani KABP® 054 live strain or **postbiotic**

Cognitive health

MINDBIOME®

L. plantarum KABP® 051

MINDBIOME® PLUS

L. plantarum KABP® 051
L. brevis KABP® 052
L. plantarum KABP® 023

Cardiometabolic health

LIPIGO®

Saccharomyces cerevisiae
postbiotic (BGCC extract)

AB-LIFE®

L. plantarum KABP® 011
L. plantarum KABP® 012
L. plantarum KABP® 013

Immune health

AB-DR7

L. plantarum KABP® 051

AB21®

L. plantarum KABP® 033
L. plantarum KABP® 022
L. plantarum KABP® 023
P. acidilactici KABP® 021

Healthy ageing

INNERIM®

L. plantarum KABP® 031
L. plantarum KABP® 032

LB-P12

L. sakei LB-P12

Eye health

AB-PROTEARS®

L. sakei KABP® 065 **postbiotic**

Women's health

GYNTIMA® CYSCARE

L. plantarum KABP® 062
L. plantarum KABP® 063

GYNTIMA® MENOPAUSE

L. plantarum KABP® 051
L. brevis KABP® 052
P. acidilactici KABP® 021

GYNTIMA® RESTORE

L. plantarum KABP® 061
live strain or **postbiotic**

GYNTIMA® BALANCE

L. gasseri KABP® 064

GYNTIMA® IRON

L. lactis H-61 **postbiotic**

Skin health

AB-SAKEI 65®

L. sakei KABP® 065 live strain or **postbiotic**

Our unique strains

Strain designation	Mechanism of action
<i>Pediococcus acidilactici</i> KABP® 021	→ Antagonistic activity against FGIDs-related bacteria → Synthesis of SCFA (acetate)
<i>Lactiplantibacillus plantarum</i> KABP® 022	→ Enhancement of the intestinal barrier via synthesis of poly-P granules → Reduction of inflammation through the production of acetylcholine
<i>Lactiplantibacillus plantarum</i> KABP® 023	→ Antagonistic activity against FGIDs-related pathogenic bacteria → Synthesis of SCFA (acetate) → Activation of genes involved in intestinal cell structure and function (CYP1A1, β-actin) → Stimulation of a key detoxification pathway through indole production
<i>Lacticaseibacillus rhamnosus</i> GG	→ Strong adhesive capacity to the intestinal epithelium → Modulation of the innate and adaptive immune responses → Synthesis of p40 and p75 proteins, that protect the epithelial barrier, enhance intestinal cells' function and promote the production of IgA → Antagonistic activity against gastrointestinal tract pathogens
<i>Bifidobacterium longum</i> KABP® 042	→ Digestion of HMOs, promoting the growth of gut Bifidobacteria → Synthesis of SCFA (acetate) → Inhibition of pathogens through the production of organic acids and bacteriocins → Synergistic protection of the intestinal barrier via upregulation of tight junction proteins
<i>Pediococcus pentosaceus</i> KABP® 041	→ Induction of anti-inflammatory cytokine IL-10 and reduction of pro-inflammatory cytokines → Inhibition of pathogens through the production of organic acids and bacteriocins → Synergistic protection of the intestinal barrier via production of poly-P granules (activation of HSP27)
<i>Lactiplantibacillus plantarum</i> KABP® 051	→ Effective colonization of the oral cavity, thanks to high resistance to oral conditions, good adherence to oral tissues and high ability to form aggregates
<i>Levilactobacillus brevis</i> KABP® 052	→ Inhibition of oral pathogens associated with gingivitis and periodontitis
<i>Pediococcus acidilactici</i> KABP® 053	→ Modulation of mucosal immunity reducing the synthesis of several inflammatory cytokines (IL-1β, IL-8)
<i>Streptococcus dentisani</i> KABP® 054	→ Inhibition of 20 different bacteria species implicated in oral disease → Regulation of oral pH, balancing the oral environment after a meal → Synthesis of anti-inflammatory cytokine IL-10

Our unique strains

Strain designation	Mechanism of action
<i>Lactiplantibacillus plantarum</i> KABP® 011	→ Modulation of bile acid metabolism via BSH production , initiating a cascade of beneficial metabolic effects
<i>Lactiplantibacillus plantarum</i> KABP® 012	→ Capacity to capture intestinal cholesterol , promoting its excretion
<i>Lactiplantibacillus plantarum</i> KABP® 013	→ Reduction of apolipoprotein (Apo) B100 and ApoB48 in plasma, two accurate markers of cardiovascular risk
<i>Saccharomyces cerevisiae</i> postbiotic	→ Specific binding to saturated fats , limiting its absorption through the intestinal wall
<i>Lactobacillus plantarum</i> KABP® 051 (DR7®)	→ Regulation of neuroactive molecules, with effects on the serotonin-kynurenine pathway and dopamine-norepinephrine pathway → Gut microbiota modulation, increasing bacteria diversity → Reduction of stress-associated molecules (cortisol) plasma levels. → Improvement of anti-inflammatory (IL-10) versus pro-inflammatory (TNF-α, IFN-γ) signals → Antioxidative properties → Antagonistic activity against pathogens linked with URTIs
<i>Levilactobacillus brevis</i> KABP® 052	→ Modulation of estrobolome function through high β-glucuronidase (GUS) activity → High GABA production supporting psychological functions
<i>Lactiplantibacillus plantarum</i> KABP® 031	→ Synthesis of acetate linked with an increase in IgA reinforcing the intestinal barrier and increasing immune protection
<i>Lactiplantibacillus plantarum</i> KABP® 032	→ Modulation of several anti and proinflammatory cytokines → Activation of key immune cells and reduction of TGF-β1 contributing to a healthier gut environment
<i>Lactiplantibacillus plantarum</i> KABP® 033	→ High plnG gene activity, boosting the adaptative immune response by direct cross-talk with dendritic cells and macrophages → Increased production of specific antibodies
<i>Latilactobacillus sakei</i> KABP® 065 (proBio 65)	→ Stimulation of regulatory lymphocytes, linked with an increased production of several cytokines (IL-10, IL-12, IL-17, IFN-γ) → Reduction of chemokines associated with allergic responses and inflammatory processes, at systemic and local levels → Antimicrobial activity against bacteria associated with atopic dermatitis

Our unique strains

Strain designation	Mechanism of action
<i>Lactiplantibacillus plantarum</i> KABP® 062	→ Antimicrobial effect against uropathogenic bacteria
<i>Lactiplantibacillus plantarum</i> KABP® 063	→ Biofilm formation and acidification capacity, preventing overgrowth of undesirable bacteria in the urinary tract
<i>Lactiplantibacillus plantarum</i> KABP® 061 (11001)	→ Antagonistic activity against pathogenic bacteria causing infections such as bacterial vaginosis, balancing vaginal microbiota → High adhesion capacity to the vaginal epithelium → Acidification of the vagina preventing overgrowth of undesirable bacteria → Antimicrobial effect against <i>Candida</i> spp.
<i>Lactobacillus gasseri</i> KABP® 064	→ Antimicrobial activity against a broad range of uropathogenic microorganisms causative of vaginal infections and linked to negative reproductive outcomes → High adhesion capacity to the vaginal epithelium → Tolerance to vaginal conditions including high concentrations of biogenic amines → High resistance to the gastrointestinal tract passage with vaginal colonization capacity after oral administration
<i>Lactococcus lactis</i> subs. <i>cremoris</i> H-61	→ Enhancement of the absorption of dietary iron through production of lactic acid → Suppression of cell apoptosis via downregulation of gene Bak1
<i>Latilactobacillus sakei</i> LB-P12	→ Suppression of the NF-κB pathway to reduce the production of pro-inflammatory molecules, including TNF-α, IL-6, and IL-1β, decreasing joint inflammation. → Downregulation of the cartilage-degrading enzyme MMP-13

Our probiotic solutions

Gastrointestinal health

i3.1®

P. acidilactici KABP® 021
L. plantarum KABP® 022
L. plantarum KABP® 023
 3 billion CFU/dose

**Indications**

- Irritable bowel syndrome (IBS)
- Stress-related digestive disorders
- Food intolerances (lactose and fructose)
- For easy digestions and good intestinal transit

Finished formulas

- Probiotic alone
- Probiotic + Vitamin D
- Probiotic + Vitamin D + Butyrate
- Probiotic + Vitamins D3, B2, B1 + Zinc + Calcium (complies FSMP regulations)



FOOD



CAPSULES



STICKS



DROPS

Scientific evidence

1. Lorenzo-Zúñiga V, et al. i3.1, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. *World J. Gastroenterol.* 20, 8709–8716 (2014).
2. Barraza-Ortiz DA, et al. Combination of a probiotic and an antispasmodic increases quality of life and reduces symptoms in patients with irritable bowel syndrome: a pilot study. *Dig. Dis.* (2020).
3. Cano-Contreras A, et al. Efficacy of probiotic i3.1 symptomatic improvement in patients with lactose intolerance. *J Clin. Gastroenterol.* (2020).
4. Lorén V, et al. Comparative effect of the i3.1 probiotic formula in two animal models of colitis. *Probiotics Antimicrob. Proteins.* 9, 71–80 (2017).
5. Perez M, et al. Derived postbiotics of a multi-strain probiotic formula clinically validated for the treatment of Irritable bowel syndrome. *FASEB J.* 34, 1–1 (2020).
6. Sato, T. et al. A probiotic blend improves defecation, mental health, and productivity in healthy Japanese volunteers under stressful situations. *Heliyon* 8, (2022).
7. Jouët, P, et al. Probiotics plus vitamin D in irritable bowel syndrome: a prospective multicentric non-interventional study. *Minerva gastroenterology* (2024).
8. Barbaro, M. R. et al. *Lactiplantibacillus plantarum* (CECT7484 and CECT7485) and *Pediococcus acidilactici* (CECT7483) enhance actin cytoskeleton and CYP1A1 expression restoring epithelial permeability alterations induced by irritable bowel syndrome mediators. *Gut Microbes* 17, (2025).
9. Portincasa, P. et al. Clinical and Metabolomic Effects of *Lactiplantibacillus plantarum* and *Pediococcus acidilactici* in Fructose Intolerant Patients. *Nutrients* 14, 2488 (2022).

AB-DIGEST

B. longum KABP® 042
P. pentosaceus KABP® 041
L. rhamnosus GG
 6 billion CFU/dose

Indications

- Antibiotic-associated diarrhea in adults and children
- Constipation
- Gut microbiota restoration
- Immune support

Finished formulas

- Probiotic + Inulin + Fructooligosaccharides (FOS) + Zinc
- Probiotic + Psyllum



SHOTS



STICKS



DROPS

Scientific evidence*

1. Hempel S, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA.* 9, 1959–69 (2012).
2. Szajewska H, et al. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults. *Aliment. Pharmacol. Ther.* 42, 1149–57 (2014).
3. Astó E, et al. Equivalence of a novel *Lactobacillus rhamnosus* isolate to the reference ATCC53103 strain. Poster presented at SEPyP congress (2018).
4. Astó E et al. Probiotic Properties of *Bifidobacterium longum* KABP® 042 and *Pediococcus pentosaceus* KABP® 041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. *Front Microbiol* 12, (2022).
5. Espadaler-Mazo J et al. *Bifidobacterium longum* KABP042 utilizes Human Milk Oligosaccharides to boost production of polyphosphate granules, strengthening intestinal barrier. Poster presented at ESPGHAN congress (2023).

Our probiotic solutions

Pediatric health

AB-KOLICARE®

B. longum KABP® 042
P. pentosaceus KABP® 041
 1 billion CFU/dose



Indications

- Infant colic
- Functional gastrointestinal disorders (FGIDs) in babies and toddlers
- For a healthy gut microbiota development during the first 1000 days

Finished formulas

- Probiotic alone
- Probiotic + HMOs
- Probiotic + Vitamin D



INFANT
FORMULA



DROPS

Scientific evidence

- Chen K. et al. Infantile colic treated with *Bifidobacterium longum* CECT7894 and *Pediococcus pentosaceus* CECT8330: A randomized, double-blind, placebo-controlled trial. *Frontiers in Pediatrics* 0, 939 (2021).
- Asto E et al. Probiotic Properties of *Bifidobacterium longum* KABP® 042 and *Pediococcus pentosaceus* KABP® 041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. *Front Microbiol* 12, (2022).
- Santas JM, et al. *Pediococcus pentosaceus* CECT 8330 and *Bifidobacterium longum* CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. *Int J Pharm Bio Sci.* 6, 458-466 (2015).
- Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. *Int. J. pharma Bio Sci.* 8, 281-288 (2017).
- Dong F et al. *Pediococcus pentosaceus* CECT 8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice. *Journal of Translational Medicine* 20, 1-16 (2022).

Scientific evidence (continued)

- Xiao, F., Dong, F., Li, X., Li, Y., Yu, G., Liu, Z., Wang, Y., & Zhang, T. *Bifidobacterium longum* CECT 7894 improves the efficacy of infliximab for DSS-induced colitis via regulating the gut microbiota and bile acid metabolism. *Frontiers in Pharmacology*, 13, 902337. (2022).
- Espadaler-mazo et al. *Bifidobacterium longum* KAPB042 utilizes human milk oligosaccharides to boost production of polyphosphate granules, strengthening intestinal barrier. *JPGN*, volume 76, Supplement 1, June 2023. Poster accepted at ESPGHAN congress (2023).
- Alcántara C, Perez M, Huedo P, et al. Study of the biosynthesis and functionality of polyphosphate in *Bifidobacterium longum* KABP042. *Sci Rep.* 13(1):11076. (2023)
- Moreno-Villares, J.M., et al. Comparative efficacy of probiotic mixture *Bifidobacterium longum* KABP042 plus *Pediococcus pentosaceus* KABP041 vs. *Limosilactobacillus reuteri* DSM17938 in the management of infant colic: a randomized clinical trial. *Eur J Pediatr* (2024).

For more info visit:

ab-biotics.com/ab-kolicare



Our probiotic solutions

Oral health

AB-DENTALAC®

L. plantarum KABP® 051

L. brevis KABP® 052

P. acidilactici KABP® 053

1 billion CFU/dose

Indications

- Gingivitis and periodontitis
- Faster recovery after oral surgery
- Bad breath
- Oral microbiota balance

Finished formulas

- Probiotic alone
- Probiotic + Vitamin D



TABLETS



VIALS



GUMS

Scientific evidence

1. Nart J et al. Oral colonization by *Levilactobacillus brevis* KABP 052 and *Lactiplantibacillus plantarum* KABP 051: A randomized, double-blinded, placebo-controlled trial (pilot study). J Clin Exp Dent 13, 433–439 (2021).
2. Montero E, et al. Clinical and microbiological effects of the adjunctive use of probiotics in the treatment of gingivitis: A randomized controlled clinical trial. J. Clin. Periodontol. 44, 708–716 (2017).
3. Ferrés-Amat E, et al. Probiotics diminish the post-operative pain following mandibular third molar extraction: A randomised double-blind controlled trial (pilot study). Benef. Microbes 11, 631–639 (2020).
4. Calabuig RP, et al. Oral probiotic reduces pain after third molar extraction procedure. Poster presented at SEPyP congress (2019).
5. Bosch M, et al. Isolation and characterization of probiotic strains for improving oral health. Arch Oral Biol. 57, 539–349 (2012).

DENTISANI

S. dentisani KABP® 054
2.5 billion CFU/dose

new!

Indications

- Dental caries
- Bad breath
- Maintains a clean, plaque-free mouth

Finished formulas

- Postbiotic + Fluoride
- Postbiotic + Active charcoal + Fluoride
- Postbiotic + Aloe vera + Fluoride



ORAL GEL



TOOTHPASTE

Scientific evidence

1. Ferrer, M. D. et al. Topic Application of the Probiotic *Streptococcus dentisani* Improves Clinical and Microbiological Parameters Associated With Oral Health. *Front Cell Infect Microbiol* 10, 465 (2020).
2. Ferrer, M. D. et al. A pilot study to assess oral colonization and pH buffering by the probiotic *Streptococcus dentisani* under different dosing regimes. *Odontology* 2019 108:2 108, 180–187 (2019).
3. Llena, C. et al. Antimicrobial efficacy of the supernatant of *Streptococcus dentisani* against microorganisms implicated in root canal infections. *J Oral Sci* 61, 184–194 (2019).
4. Esteban-Fernández, A. et al. Inhibition of oral pathogens adhesion to human gingival fibroblasts by wine polyphenols alone and in combination with an oral probiotic. *J Agric Food Chem* 66, 2071–2082 (2018).
5. Camelo-Castillo, A., et al. *Streptococcus dentisani* sp. nov., a novel member of the mitis group. *Int J Syst Evol Microbiol* 64, 60–65 (2014).

Scientific evidence (continued)

6. López-López, A. et al. Health-associated niche inhabitants as oral probiotics: The case of *Streptococcus dentisani*. *Front Microbiol* 8, 379 (2017).
7. Esteban-Fernández, A. et al. In vitro beneficial effects of *Streptococcus dentisani* as potential oral probiotic for periodontal diseases. *J Periodontol* 90, 1346–1355 (2019).
8. López-Santacruz, H. D. et al. *Streptococcus dentisani* is a common inhabitant of the oral microbiota worldwide and is found at higher levels in caries-free individuals. *International Microbiology* 2021 24:4 24, 619–629 (2021).
9. Ferrer, M. D. et al. Evaluation of clinical, biochemical and microbiological markers related to dental caries. *Int J Environ Res Public Health* 18, (2021).
10. Conrads, G. et al. Isolation and bacteriocin-related typing of *Streptococcus dentisani*. *Front Cell Infect Microbiol* 9, 110 (2019).

Our probiotic solutions

Cognitive health

MINDBIOME®

L. plantarum KABP® 051
1 billion CFU/dose



Indications

- Stress and anxiety
- Emotional wellbeing
- Memory and cognition
- To sleep and rest better
- Improved energy levels
- Weight management

Finished formulas

- Probiotic alone
- Probiotic + Magnesium
- Probiotic + Melatonin
- Probiotic + Ashwagandha + GABA + Vitamin B6



FOOD



CAPSULES



STICKS

Scientific evidence

1. Chong HX, et al. *Lactobacillus plantarum* DR7 alleviates stress and anxiety in adults: A randomised, double-blind, placebo-controlled study. *Benef. Microbes* 10, 355–373 (2019).
2. Liu G, et al. *Lactobacillus plantarum* DR7 modulated bowel movement and gut microbiota associated with dopamine and serotonin pathways in stressed adults. *Int. J. Mol. Sci.* 21, 4608 (2020).
3. Lew LC, et al. Effects of potential probiotic strains on the fecal microbiota and Metabolites of d-Galactose-Induced Aging Rats Fed with High-Fat Diet. *Probiotics Antimicrob. Proteins* 12, 545–562 (2020).
4. Talbott, S. et al. Effects of *Lactiplantibacillus plantarum* KABP051 Probiotic on Body Composition, Microbiome and Mood in Healthy Overweight Adults. *J. Med. Food* (2025).

MINDBIOME® PLUS

L. plantarum KABP® 051
L. brevis KABP® 052
L. plantarum KABP® 023
1 billion CFU/dose

Indications

- Hyperactivity and impulsivity
- Cognitive function
- Memory and learning

Finished formulas

- Probiotic alone
- Probiotic + Magnesium



CAPSULES



STICKS

Scientific evidence

1. Chong HX, et al. *Lactobacillus plantarum* DR7 alleviates stress and anxiety in adults: A randomised, double-blind, placebo-controlled study. *Benef. Microbes* 10, 355–373 (2019).
2. Liu G, et al. *Lactobacillus plantarum* DR7 modulated bowel movement and gut microbiota associated with dopamine and serotonin pathways in stressed adults. *Int. J. Mol. Sci.* 21, 4608 (2020).
3. Lew LC, et al. Effects of potential probiotic strains on the fecal microbiota and Metabolites of d-Galactose-Induced Aging Rats Fed with High-Fat Diet. *Probiotics Antimicrob. Proteins* 12, 545–562 (2020).
4. Rojo-Marticella, M., et al. Effect of Probiotics on the Symptomatology of Autism Spectrum Disorder and/or Attention Deficit/Hyperactivity Disorder in Children and Adolescents: Pilot Study. *Res Child Adolesc Psychopathol* 53, 163–178 (2025).
5. Quesada Rodriguez, M. J., et al. Effects Of A Probiotic Formulation After Experimentally Induced Stress In An Adult Population. *Clinical Nutrition ESPEN*, 54(12), 650 (2023).

Our probiotic solutions

Cardiometabolic health

AB-LIFE®

L. plantarum KABP® 011
L. plantarum KABP® 012
L. plantarum KABP® 013
1.2 billion CFU/dose



Indications

- Dyslipidemia
- Cardiometabolic dysfunction
- Insulin sensitivity and satiety

Finished formulas

- Probiotic alone
- Probiotic + Vitamin B1
- Probiotic + Omega 3 (ALA)
- Probiotic + Monacolin K



CAPSULES



STICKS



DROPS

Scientific evidence

1. Fuentes, M. C., Lajo, T., Carrión, J. M. & Cuñé, J. Cholesterol-lowering efficacy of *Lactobacillus plantarum* CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. Br. J. Nutr. 109, 1866–1872 (2013)
2. Espadaler J, et al. Demographic and clinical characteristics influencing the effects of a cholesterol-lowering probiotic. Ann. Nutr. Metab. 74, 1–31 (2019).
3. Bosch M, et al. *Lactobacillus plantarum* CECT 7527, 7528 and 7529: Probiotic candidates to reduce cholesterol levels. J. Sci. Food Agric. 94, 803–809 (2014).
4. Kim DH, et al. Effect of mixture of *Lactobacillus plantarum* CECT 7527, 7528, and 7529 on obesity and lipid metabolism in rats fed a high-fat diet. J. Korean Soc. Food Sci. Nutr. 43, 1484–1490 (2014).
5. Mukerji P, et al. Safety evaluation of AB-LIFE®. Antibiotic resistance and 90-day repeated-dose study in rats. Food Chem. Toxicol. 92, 117–128 (2016).
6. Guerrero-Bonmatty, R et al. A Combination of *Lactopantibacillus plantarum* strains CECT7527, CECT7528, and CECT7529 plus monacolin K reduces blood cholesterol: Results from a randomized, double-blind, placebo-controlled Study. Nutrients 2021, Vol. 13, Page 1206 13, 1206 (2021).
7. Padro T, de Santisteban V, Huedo P, et al. *Lactiplantibacillus plantarum* strains KABP011, KABP012 and KABP013 modulate bile acids and cholesterol metabolism in humans. Cardiovasc Res. Published online March 25, 2024.
8. Kerlikowsky, F., Müller, M., Greupner, T. et al. Distinct Microbial Taxa Are Associated with LDL-Cholesterol Reduction after 12 Weeks of *Lactobacillus plantarum* Intake in Mild Hypercholesterolemia: Results of a Randomized Controlled Study. Probiotics & Antimicro. Prot. (2023).

LIPIGO®

Saccharomyces cerevisiae postbiotic
(BGCC extract)

3000 mg/dose
Class IIb Medical Device (MDR)



Indications

- Prevents rebound effect
- Safe weight loss
- Overweight and type I obesity

Finished formulas

- Postbiotic alone



STICKS

Scientific evidence

1. Santas J, et al. Effect of a polysaccharide-rich hydrolysate from *Saccharomyces cerevisiae* (LipiGO®) in body weight loss: randomised, double-blind, placebo-controlled clinical trial in overweight and obese adults. J Sci Food Agric. 97, 4250–7 (2017).
2. Valero-Pérez, M. et al. Regular consumption of Lipigo® promotes the reduction of body weight and improves the rebound effect of obese people undergo a comprehensive weight loss program. Nutrients 2020, Vol. 12, Page 1960 12, 1960 (2020).
3. Santas J, et al. Polysaccharide-rich hydrolysate from *Saccharomyces cerevisiae* (LipiGO®) increases fatty acid and neutral sterol excretion in guinea pigs fed with hypercholesterolemic diets. Eur J Lipid Sci Technol. 119, 17001–04 (2017).

Our probiotic solutions

Immune health

AB-DR7

L. plantarum KABP® 051
1 billion CFU/dose



Indications

- Upper respiratory tract infections (URTIs)
- Respiratory health
- Immunity support

Finished formulas

- Probiotic alone
- Probiotic + Vitamin D
- Probiotic + Vitamin C
- Probiotic + Zinc



CAPSULES



STICKS



DROPS

Scientific evidence

- Chong HX, et al. *Lactobacillus plantarum* DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study. *J. Dairy Sci.* 102, 4783–4797 (2019).
- Altadill T, et al. Does *Lactopantibacillus plantarum* DR7 reduce days of upper respiratory tract infections and fever? A post-hoc analysis of a randomized, placebo-controlled trial. *FASEB Journal* (2021).
- Baud D, et al. Using probiotics to flatten the curve of coronavirus disease COVID-2019. *Pandemic. Front. Public Heal.* 8, (2020).
- Low LC, et al. Effects of potential probiotic strains on the fecal microbiota and metabolites of d-galactose-induced aging rats fed with high-fat diet. *Probiotics Antimicrob. Proteins.* 12, 545–562 (2020).

AB21®

L. plantarum KABP® 033
L. plantarum KABP® 022
L. plantarum KABP® 023
P. acidilactici KABP® 021

2 billion CFU/dose



Indications

- Viral respiratory infections in adults and children
- To boost adaptive immunity (specific antibody production)
- Mild to moderate COVID-19 symptoms

Finished formulas

- Probiotic alone
- Probiotic + Vitamin D
- Probiotic + Zinc



CAPSULES



STICKS



DROPS

Scientific evidence

- Gutiérrez-Castrellón, P. et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. *Gut Microbes* 14, (2022).
- Gutierrez-Castrellon, P., et al. Probiotic effect on SARS-CoV2 immunity is associated to type-I interferons: A post-hoc analysis of a randomized, placebo-controlled trial. *The FASEB Journal* 36, (2022).
- Espadaler Mazo et al. Eficacia y seguridad del probiótico AB21 en niños con infecciones respiratorias comunes de origen vírico. *Anales de Microbiota, Probióticos y Prebióticos.* Vol. 5 · Nº 1, p. 195 (2024).
- Altadill, T et al. Probiotic blend of *L. plantarum* and *P. acidilactici* (AB21) stimulates type-I interferon response in phagocytes with the participation of the IRF7 transcription factor, possibly involving both MyD88-dependent and independent mechanisms. *Journal of Biological Chemistry* 300, 105827 (2024).
- Andrade-Platas, D., et al. A probiotic containing *L. plantarum* and *P. acidilactici* strains for treating upper respiratory infection in children aged 6 months to 5 years: a randomized, double-blind trial. *Eur. J. Pediatr.* 184, (2025).

Our probiotic solutions

Healthy ageing

INNERIM®

L. plantarum KABP® 031
L. plantarum KABP® 032
1 billion CFU/dose

Indications

- Immune ageing
- Nutrition deficiency
- Constipation

Finished formulas

- Probiotic alone
- Probiotic + Vitamin B9 + B6 + B12 + C + A + Zinc + Selenium + CoQ10



CAPSULES



STICKS



DROPS

Scientific evidence

1. Singh, R. G. et al. Efficacy of Probiotic Supplementation with *Lactiplantibacillus plantarum* Strains on Gastrointestinal Tract Function – A Randomized Controlled Trial. *J Diet Suppl* 22, 549–570 (2025).
2. Bosch M, et al. Probiotic properties of *Lactobacillus plantarum* CECT 7315 and CECT 7316 isolated from faeces of healthy children. *Lett. Appl. Microbiol.* 54, 240–246 (2012).
3. Mañé J, et al. A mixture of *Lactobacillus plantarum* CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial. *Nutr. Hosp.* 26, 228–235 (2011).
4. Bosch M, et al. *Lactobacillus plantarum* CECT 7315 and CECT 7316 stimulate immunoglobulin production after influenza vaccination in elderly. *Nutr. Hosp.* 27, 504–509 (2012).
5. Vilahur G, et al. *Lactobacillus plantarum* CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response. *Eur. J. Nutr.* 54, 1161–1171 (2015).

LB-P12

L. sakei LB-P12
10 billion cfu/dose

new!

Indications

- Chronic joint pain (osteoarthritis)
- Overall joint health

Finished formulas

- Probiotic alone



CAPSULES

Scientific evidence

1. Shine, B. K. et al. Efficacy and safety of *Latilactobacillus sakei* LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial. *Sci Rep* 15, 1–14 (2025).
2. Song, M., Kim, W. J., Shim, J. & Song, K. *Latilactobacillus sakei* LB-P12 Ameliorates Osteoarthritis by Reducing Cartilage Degradation and Inflammation via Regulation of NF-κB/HIF-2α Pathway. *J. Microbiol. Biotechnol.* 35, 1–10 (2025).

Our probiotic solutions

Eye health

AB-PROTEARS®

L. sakei KABP® 065

1 billion CFU/dose
Class IIb Medical Device (MDR)

Indications

- Dry eye or ocular irritation
- Allergies and inflammation of the eye surface

Finished formulas

- Lysate (postbiotic) + Hypromellose



EYE DROPS

Scientific evidence

1. Iorio, R. et al. *Lactobacillus sakei* pro-bio65 reduces $\text{tnf-}\alpha$ expression and upregulates gsh content and antioxidant enzymatic activities in human conjunctival cells. *Transl Vis Sci Technol* 10, (2021).
2. Heydari M, et al. The Effect of Ophthalmic and Systemic Formulations of *Latilactobacillus sakei* on Clinical and Immunological Outcomes of Patients With Dry Eye Disease: A Factorial, Randomized, Placebo-controlled, and Triple-masking Clinical Trial. *Probiotics Antimicrob Proteins*. 2023 May 31. Epub ahead of print. PMID: 37256485.

Our probiotic solutions

Women's health

GYNTIMA[®] CYSCARE

L. plantarum KABP[®] 062
L. plantarum KABP[®] 063
1 billion CFU/dose

Indications

- Urinary tract infections (UTIs)
- Urogenital microbiota balance



Finished formulas

- Probiotic alone
- Probiotic + Cranberry extract + Vitamin C + D-mannose



CAPSULES



STICKS

Scientific evidence

1. Simón E, et al. Screening of *Lactobacilli* strains of human origin candidates for the prevention of urinary tract infections. *Ann. Nutr. Metab.* 74, 1–31 (2019).
2. Effective use of a *Lactiplantibacillus plantarum* mixture with cranberry and vitamin C in the reduction of recurrence of urinary tract infections in women: a randomized controlled trial. *Manuscript under preparation*.
3. Padayatty SJ, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. *J Am Coll Nutr.* 22, 18–35 (2003)
4. Wang CH, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med.* 172, 988–96 (2012).
5. Salo J, et al. Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized controlled trial. *Clin Infect Dis.* 54, 340–6 (2012).

GYNTIMA[®] RESTORE

L. plantarum KABP[®] 061
Class IIb Medical Device (MDR)

Indications

- Vaginal candidiasis
- Vaginosis

Finished formulas

- Postbiotic (heat-inactivated strain) + Lactic acid
- Probiotic alone



VAGINAL
TABLETS

Scientific evidence

1. Palacios S, et al. Is it possible to prevent recurrent vulvovaginitis? Role of *Lactobacillus plantarum* II001 (CECT7504). *Eur J Clin Microbiol. Infect. Dis.* 35, 1701–8 (2016).
2. Bonachera-Sierra MA, et al. Heat-inactivated *Lactiplantibacillus plantarum* KABP 061 exerts antipathogenic activity against causative agents of vulvovaginal candidiasis. Poster presented at IHMC Congress, Kobe, Japan (2022).

GYNTIMA® MENOPAUSE

L. plantarum KABP® 051
L. brevis KABP® 052
P. acidilactici KABP® 021
1 billion CFU/dose



new!

Indications

- Estrogen level decline
- Menopause-related symptoms

Finished formulas

- Probiotic alone
- Probiotic + Vitamin D + Vitamin B9 + Vitamin B6
- Probiotic + Vitamin B6 + Vitamin B7 + Vitamin D + Black cohosh + Magnesium + Melatonin (day and night capsules)



CAPSULES



STICKS

Scientific evidence

1. Honda et al. Supplementation with a Probiotic Formula Having Glucuronidase Activity Modulates Serum Estrogen Levels in Healthy Peri- and Postmenopausal Women. *J Med Food* (2024).

GYNTIMA® BALANCE

L. gasseri KABP® 064
1 billion CFU/dose

new!

Indications

- Vaginal microbiota imbalance
- Immune support for sustained comfort and protection

Finished formulas

- Probiotic alone
- Probiotic + Vitamin D + Biotin + Selenium + Zinc



CAPSULES

Scientific evidence

1. Perez, M. et al. *Lactobacillus gasseri* CECT 30648 shows probiotic characteristics and colonizes the vagina of healthy women after oral administration. *Microbiol Spectr* 13, e00211-25 (2025).

2. Huedo, P. et al. Whole-genome sequences of vaginal isolates *Lactobacillus crispatus* CECT30647 and *Lactobacillus gasseri* CECT30648. *Microbiol Resour Announc* 13, e0079424 (2024).

GYNTIMA[®] IRON

L. lactis subs. *cremoris* H-61
60 mg/dose

new!

Indications

- Iron deficiency
- Increased iron demands due to sports performance
- Skin health during ageing

Finished formulas

- Postbiotic alone
- Postbiotic + Iron



CAPSULES

Scientific evidence

1. Takaragawa, M., et al. Heat-Killed *Lactococcus lactis* subsp. *cremoris* H61 altered the iron status of young women: A randomized, double-blinded, placebo-controlled, parallel-group comparative study. *Nutrients* 14, 3144 (2022).
2. Suzuki, Y. et al. *Lactococcus lactis* subsp. *cremoris* H61 improved iron status in male distance runners. *Int. J. Anal. Bio-Sci.* 10, 33–41 (2022).
3. Kimoto-Nira, H., et al. Oral intake of heat-killed cells of *Lactococcus lactis* strain H61 promotes skin health in women. *J Nutr Sci* 1, 1–7 (2012).
4. Oike, H. et al. Dietary intake of heat-killed *Lactococcus lactis* H61 delays age-related hearing loss in C57BL/6J mice. *Sci Rep* 6, 1–9 (2016).

Our probiotic solutions

Skin health

AB-SAKEI 65®

L. sakei KABP® 065

5 billion CFU/dose

Indications

- Atopic dermatitis
- Skin irritation, redness and discomfort
- Promotes skin hydration and elasticity to prevent wrinkles

Finished formulas

- Probiotic alone
- Probiotic + Zinc
- Probiotic + Niacin + Vitamin C
- Postbiotic alone (lysate)
- Postbiotic + Collagen + Hyaluronic acid + Vitamin C + Coenzyme Q10

BEAUTY
SHOTS

CAPSULES



STICKS



CREAM



GUMMIES

Scientific evidence

1. Woo SI, et al. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. *Ann. Allergy, Asthma Immunol.* 104, 343–348 (2010).
2. Park SB, et al. Effect of emollients containing vegetable-derived lactobacillus in the treatment of atopic dermatitis symptoms: Split-body clinical trial. *Ann. Dermatol.* 26, 150–155 (2014).
3. Rather IA, et al. Oral administration of live and dead cells of *Lactobacillus sakei* proBio65 alleviated atopic dermatitis in children and adolescents: a randomized, double-blind, and placebo-controlled Study. *Probiotics Antimicrob. Proteins* (2020).
4. Lim J, et al. Immune-modulating characteristics of *Lactobacillus sakei* proBio65 isolated from Kimchi. *Korean J. Microbiol. Biotechnol.* 39, 313–316 (2011).
5. Kim JY, et al. Atopic dermatitis-mitigating effects of new *Lactobacillus* strain, *Lactobacillus sakei* probio 65 isolated from Kimchi. *J. Appl. Microbiol.* 115, 517–526 (2013).

Scientific evidence (continued)

6. Sawashita, J. et al. Novel Application of Oral Postbiotics for Skin Condition in Healthy Middle-Aged Women: A Randomized, Double-Blind, and Placebo-Controlled Study. *J. Cosmet. Dermatol.* 24, (2025).

Our available formats

Our available formats

CAPSULES



- 5 capsules
- 15 capsules
- 30 capsules (cap-in-cap)
- 60 capsules (cap-in-cap)
- bulk

MICROENCAPSULATED CAPSULES



- 5 capsules
- 15 capsules
- 30 capsules
- bulk

Probiotics microencapsulated with PROBS® technology, to ensure stability when mixed with specific ingredients like Cranberry extract

STICKS



- 2 sticks
- 20 sticks
- 30 sticks
- 42 sticks
- 90 sticks
- bulk

SHOTS



- 5 shots
- 7 shots
- 10 shots
- bulk

BLUE OR INLINE DROPPER



- 3ml shots
- 8ml shots
- 10ml shots
- bulk

Our available formats

EYE DROPPER



- 3ml dropper
- 8ml dropper

ORAL GUMS



- 8 tablets

ORAL TABLETS



- 5 tablets
- 10 tablets
- 15 tablets
- 30 tablets
- 60 tablets
- bulk

VIAL



- 3ml
- 8ml shots
- 10ml shots
- bulk

VAGINAL TABLETS



- 7 tablets + 1 applicator
- 7 tablets no applicator
- 7 tablets blister in bulk
- 7 tablets + 7 applicator

Our available formats

TOOTHPASTE



- 7ml
- 75ml

CREAM



- Solid cream
- Plastic stick
- Carton stick

BEAUTY SHOTS



- 14 shots
- 28 shots

MULTILAYER TABLETS



- 30 tablets
- 60 tablets

SACHET



- 14 sachets

SERUM



- 50ml
- 60ml

Our global footprint gives us a unique view of the ever changing probiotic landscape enabling us to offer regulatory support in not only supplements, and functional foods but also OTC and medical applications to meet the needs of consumers worldwide.



www.ab-biotics.com
hello@ab-biotics.com